Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

Accipiolx

K-Number: K201310 · 2020-08-07

Decision Date2020-08-07
Product CodeQAS
Advisory CommitteeRA
DecisionSubstantially Equivalent

Device Summary

Accipiolx is the device name listed in this FDA 510(k) record. The listed applicant is Maxq AL , Ltd.. It received FDA 510(k) clearance on 2020-08-07 under 510(k) number K201310. The device is classified under product code QAS. It was reviewed by the RA advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Accipiolx?

Accipiolx is a medical device that received FDA 510(k) clearance on 2020-08-07. The listed applicant is Maxq AL , Ltd.. The 510(k) number is K201310.

When did Accipiolx receive FDA 510(k) clearance?

Accipiolx received FDA 510(k) clearance on 2020-08-07, under 510(k) number K201310.

Who is the listed applicant for Accipiolx?

The FDA 510(k) record lists Maxq AL , Ltd. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Accipiolx?

The FDA product code for Accipiolx is QAS.

Other records listing Maxq AL , Ltd. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Related Devices (Code: QAS)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.